安域生物科技

Anyu Biopharmaceutical is a clinical-stage biotechnology company dedicated to the discovery and development of small molecule drugs targeting challenging protein-protein interactions (PPIs). The company leverages its proprietary Anyu-PPI platform, which combines fragment-based drug discovery, DNA-encoded libraries, and AI-driven design to address previously undruggable targets in oncology and immunology. Its lead candidate, AY-001, is a potent SHP2 inhibitor currently undergoing clinical evaluation for the treatment of advanced solid tumors. Headquartered in Hangzhou, China, Anyu is supported by a leadership team with extensive experience from global pharmaceutical companies and is funded by top-tier venture capital firms. The company aims to provide innovative therapeutic solutions for patients with high unmet medical needs, particularly in the RAS/MAPK signaling pathway.